Biocryst Pharmaceuticals (BCRX) Cash from Financing Activities (2010 - 2026)

Biocryst Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $412.6 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 77887.15% year-over-year to $412.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.1 million (up 1584.03% YoY) and the FY2025 annual result came in at -$349.9 million, down 5974.14% from the prior year.
• Cash from Financing Activities was $412.6 million for Q1 2026 at Biocryst Pharmaceuticals, up from -$218.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $412.6 million in Q1 2026 and bottomed at -$218.0 million in Q4 2025.
• A 5-year average of $10.4 million and a median of $529000.0 in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2025 — Cash from Financing Activities tumbled 5320.54% — and 2026, when it jumped 77887.15%.
• Biocryst Pharmaceuticals' Cash from Financing Activities stood at $4.2 million in 2022, then tumbled by 175.57% to -$3.2 million in 2023, then decreased by 26.73% to -$4.0 million in 2024, then tumbled by 5320.54% to -$218.0 million in 2025, then jumped by 289.28% to $412.6 million in 2026.
• Business Quant data shows BCRX's Cash from Financing Activities at $412.6 million in Q1 2026, -$218.0 million in Q4 2025, and -$58.8 million in Q3 2025.